Chemomab Therapeutics (CMMB) Total Liabilities (2017 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Total Liabilities came in at $1.5 million in Q4 2025, down 56.87% YoY from $3.4 million in Q4 2024, and up 29.99% on a QoQ basis from $1.1 million in Q3 2025.
Chemomab Therapeutics (CMMB) Total Liabilities (2017 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 9 years of Total Liabilities data on file, last reported at $1.5 million in Q4 2025.
- Quarterly Total Liabilities fell 56.87% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.5 million (down 56.87% YoY) and the FY2025 annual result came in at $1.5 million, down 56.87% from the prior year.
- Total Liabilities grew to $1.5 million in Q4 2025, from $1.1 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $7.1 million in Q1 2023 to a low of $1.1 million in Q3 2025.
- A 5-year average of $4.1 million and a median of $4.6 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 190.2% — and 2025, when it sank 75.17%.
- Tracing CMMB's Total Liabilities over 5 years: stood at $2.9 million in 2021, then surged by 136.92% to $6.8 million in 2022, then dropped by 24.65% to $5.2 million in 2023, then plunged by 33.51% to $3.4 million in 2024, then sank by 56.87% to $1.5 million in 2025.
- The last three Total Liabilities figures came in at $1.5 million (Q4 2025), $1.1 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | 1.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 1.43 Mn |
| Mar 31, 2025 | 2.43 Mn |
| Dec 31, 2024 | 3.43 Mn |
| Sep 30, 2024 | 4.58 Mn |
| Jun 30, 2024 | 4.56 Mn |
| Mar 31, 2024 | 4.68 Mn |
| Dec 31, 2023 | 5.15 Mn |
| Sep 30, 2023 | 5.38 Mn |
| Jun 30, 2023 | 6.86 Mn |
| Mar 31, 2023 | 7.06 Mn |
| Dec 31, 2022 | 6.84 Mn |
| Sep 30, 2022 | 5.60 Mn |
| Jun 30, 2022 | 4.54 Mn |
| Mar 31, 2022 | 3.72 Mn |
| Dec 31, 2021 | 2.89 Mn |
| Sep 30, 2021 | 1.93 Mn |
| Jun 30, 2021 | 2.48 Mn |
| Mar 31, 2021 | 4.96 Mn |